Antheia nabs $73M for synthetic biology platform

June 30, 2021 -- Antheia has raised $73 million to support the commercialization of its first pharmaceutical compound and the scale-up of production of active pharmaceutical ingredients and key starting materials on its synthetic biology platform.

Read the article at The Science Advisory Board